Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study

Fabrizio Cantini, Laura Niccoli, Emanuele Cassar&agrave;, Olga Kaloudi, Carlotta NanniniDivision of Rheumatology, Misericordia e Dolce Hospital of Prato, Prato,&nbsp;ItalyPurpose: The primary purpose of this study was to evaluate the proportion of psoriatic arthritis (PsA) patients m...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cantini F, Niccoli L, Cassar&agrave; E, Kaloudi O, Nannini C
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2012
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/b389d338f8764fd4bfde7d31d615f3d4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b389d338f8764fd4bfde7d31d615f3d4
record_format	dspace
spelling	oai:doaj.org-article:b389d338f8764fd4bfde7d31d615f3d42021-12-02T07:19:14ZSustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study1177-54751177-5491https://doaj.org/article/b389d338f8764fd4bfde7d31d615f3d42012-07-01T00:00:00Zhttp://www.dovepress.com/sustained-maintenance-of-clinical-remission-after-adalimumab-dose-redu-a10381https://doaj.org/toc/1177-5475https://doaj.org/toc/1177-5491Fabrizio Cantini, Laura Niccoli, Emanuele Cassar&agrave;, Olga Kaloudi, Carlotta NanniniDivision of Rheumatology, Misericordia e Dolce Hospital of Prato, Prato,&nbsp;ItalyPurpose: The primary purpose of this study was to evaluate the proportion of psoriatic arthritis (PsA) patients maintaining clinical remission after adalimumab (ADA) dose reduction compared with patients with rheumatoid arthritis. Secondary purposes include evaluating the proportion of PsA patients who achieve remission, the duration of remission after ADA dose reduction, time to relapse, psoriasis course, and the frequency of adverse events at the end of follow-up.Methods: This was a single-center, prospective, follow-up, case-control study of 76 consecutive patients (35 females, 41 males; mean age 46 &plusmn; 10.2 years) who met the classification criteria for psoriatic arthritis and required anti-tumor necrosis factor therapy according to Group for Research and Assessment of Psoriasis and Psoriatic Arthritis recommendations. The 76 patients were compared with 55 patients (40 females, 15 males; mean age 50 &plusmn; 11.6 years) who satisfied the American College of Rheumatology criteria for rheumatoid arthritis and received the same treatment. Case patients and controls were recruited from January 2008 to December 2010. At baseline, PsA patients and controls received 40 mg of ADA every other week, usually with methotrexate (10 to 20 mg/weekly). In the presence of clinical remission, ADA dose was reduced to 40 mg every 4 weeks in both groups.Results: Fifty-three of the 76 (69.7%) PsA patients and 17 of the 55 (30.9%) rheumatoid arthritis (P &lt; 0.019) controls achieved remission after a mean time of 5.1 &plusmn; 1.2 and 6.3 &plusmn; 1.6 months, respectively (P = nonsignificant). After halving the dose of ADA, 47 of the 53 (88.6%) PsA patients and three of the 17 (17.6%) controls maintained remission (P = 0.016) over a mean follow-up period of 28.9 &plusmn; 8.4 and 24.2 &plusmn; 6.4 months, respectively. No significant changes in Psoriatic Arthritis Severity Index scores were observed. The mean time to relapse was 8.3 &plusmn; 3.4 months in six case patients and 7.2 &plusmn; 4.2 in 14 controls (P = not significant). No serious adverse events occurred in either group.Conclusion: Clinical remission is possible in a high percentage of patients with early PsA receiving ADA. Such remission is maintained in a high proportion of subjects after ADA dose halving, with relevant advantages in terms of patient compliance, drug-exposure risk, and economic burden.Keywords: psoriatic arthritis, anti-TNF, adalimumab, remission, dose reductionCantini FNiccoli LCassar&agrave; EKaloudi ONannini CDove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2012, Iss default, Pp 201-206 (2012)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Cantini F Niccoli L Cassar&agrave; E Kaloudi O Nannini C Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study
description	Fabrizio Cantini, Laura Niccoli, Emanuele Cassar&agrave;, Olga Kaloudi, Carlotta NanniniDivision of Rheumatology, Misericordia e Dolce Hospital of Prato, Prato,&nbsp;ItalyPurpose: The primary purpose of this study was to evaluate the proportion of psoriatic arthritis (PsA) patients maintaining clinical remission after adalimumab (ADA) dose reduction compared with patients with rheumatoid arthritis. Secondary purposes include evaluating the proportion of PsA patients who achieve remission, the duration of remission after ADA dose reduction, time to relapse, psoriasis course, and the frequency of adverse events at the end of follow-up.Methods: This was a single-center, prospective, follow-up, case-control study of 76 consecutive patients (35 females, 41 males; mean age 46 &plusmn; 10.2 years) who met the classification criteria for psoriatic arthritis and required anti-tumor necrosis factor therapy according to Group for Research and Assessment of Psoriasis and Psoriatic Arthritis recommendations. The 76 patients were compared with 55 patients (40 females, 15 males; mean age 50 &plusmn; 11.6 years) who satisfied the American College of Rheumatology criteria for rheumatoid arthritis and received the same treatment. Case patients and controls were recruited from January 2008 to December 2010. At baseline, PsA patients and controls received 40 mg of ADA every other week, usually with methotrexate (10 to 20 mg/weekly). In the presence of clinical remission, ADA dose was reduced to 40 mg every 4 weeks in both groups.Results: Fifty-three of the 76 (69.7%) PsA patients and 17 of the 55 (30.9%) rheumatoid arthritis (P &lt; 0.019) controls achieved remission after a mean time of 5.1 &plusmn; 1.2 and 6.3 &plusmn; 1.6 months, respectively (P = nonsignificant). After halving the dose of ADA, 47 of the 53 (88.6%) PsA patients and three of the 17 (17.6%) controls maintained remission (P = 0.016) over a mean follow-up period of 28.9 &plusmn; 8.4 and 24.2 &plusmn; 6.4 months, respectively. No significant changes in Psoriatic Arthritis Severity Index scores were observed. The mean time to relapse was 8.3 &plusmn; 3.4 months in six case patients and 7.2 &plusmn; 4.2 in 14 controls (P = not significant). No serious adverse events occurred in either group.Conclusion: Clinical remission is possible in a high percentage of patients with early PsA receiving ADA. Such remission is maintained in a high proportion of subjects after ADA dose halving, with relevant advantages in terms of patient compliance, drug-exposure risk, and economic burden.Keywords: psoriatic arthritis, anti-TNF, adalimumab, remission, dose reduction
format	article
author	Cantini F Niccoli L Cassar&agrave; E Kaloudi O Nannini C
author_facet	Cantini F Niccoli L Cassar&agrave; E Kaloudi O Nannini C
author_sort	Cantini F
title	Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study
title_short	Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study
title_full	Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study
title_fullStr	Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study
title_full_unstemmed	Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study
title_sort	sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study
publisher	Dove Medical Press
publishDate	2012
url	https://doaj.org/article/b389d338f8764fd4bfde7d31d615f3d4
work_keys_str_mv	AT cantinif sustainedmaintenanceofclinicalremissionafteradalimumabdosereductioninpatientswithearlypsoriaticarthritisalongtermfollowupstudy AT niccolil sustainedmaintenanceofclinicalremissionafteradalimumabdosereductioninpatientswithearlypsoriaticarthritisalongtermfollowupstudy AT cassarampagravee sustainedmaintenanceofclinicalremissionafteradalimumabdosereductioninpatientswithearlypsoriaticarthritisalongtermfollowupstudy AT kaloudio sustainedmaintenanceofclinicalremissionafteradalimumabdosereductioninpatientswithearlypsoriaticarthritisalongtermfollowupstudy AT nanninic sustainedmaintenanceofclinicalremissionafteradalimumabdosereductioninpatientswithearlypsoriaticarthritisalongtermfollowupstudy
_version_	1718399473785241600

Sustained maintenance of clinical remission after adalimumab dose reduction in patients with early psoriatic arthritis: a long-term follow-up study

Ejemplares similares